Latest News

Amlitelimab Demonstrates Sustained Improvements in Atopic Dermatitis Signs and Symptoms
Amlitelimab Demonstrates Sustained Improvements in Atopic Dermatitis Signs and Symptoms

March 21st 2024

Late-breaking data demonstrating the sustained improvements was presented at the American Academy of Dermatology Annual Meeting.

Connecting COVID-19 Research to Impact on Patients With Atopic Dermatitis
Connecting COVID-19 Research to Impact on Patients With Atopic Dermatitis

March 18th 2024

Red, Itchy, And AD Until Proven Otherwise
Red, Itchy, And AD Until Proven Otherwise

March 12th 2024

Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD
Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD

March 10th 2024

Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients
Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients

March 10th 2024

Video Series
Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.